Live Online Training: ICH Q12 - How to use the PACMP in Practice

Live Online Training: ICH Q12 - How to use the PACMP in Practice

Course No 18577

This course is part of the GMP Certification Programme "ECA Certified Regulatory Affairs Manager". Learn more.

Note: All times mentioned are CET.

Our Service

Costs

ECA-Member: EUR 890,--
Regular Fee: EUR 1090,--
EU/GMP Inspectorates: EUR 545,--
APIC Member Discount: EUR 990,--

(All prices excl. VAT)

Registration

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Dr Joachim Ermer, Ermer Quality Consulting
Dr Steffen Groß, PEI
Dr Ulrich Kissel, Chair of the EQPA
Dr Lisa Matzen, Boehringer Ingelheim
Luisa Paulo, Hovione, Member of the ICH Q12 IWG
Dr Ramesh Raghavachari, FDA

Objectives

The ICH Q12 topic was endorsed by the ICH Steering Committee in September 2014 and the draft ICH Q12 Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management was published for comment in December 2017. The final ICH Q12 Post-Approval Changes Guideline including two Annexes has been adopted in November 2019. The guideline aims to promote innovation and continual improvement, and strengthen quality assurance and reliable supply of product, including proactive planning of global supply chain adjustments.
The next phase will be the implementation of ICH Q12 across the ICH regions. However, especially in the EU, revision of local regulations (i.e. the EU Variations Regulation) will have to be performed to fully implement the concepts of Q12 (e.g.: the PACMP can currently be used in the US and in the EU, whereas the ECs are not yet used in the EU).
The new guideline has been developed to complement the existing ICH Q8 to Q11 guidelines, especially to enable full realization of more flexible regulatory approaches to post-approval CMC changes. The guideline applies to pharmaceutical drug substances and products (both chemical and biological). The Guideline also applies to drug-device combination products that meet the definition of a pharmaceutical or biological product and to analytical methods.
In order to ensure a standardized approach, the guidance defines the categorization of Post-Approval CMC changes, Established Conditions (ECs), Post-Approval Change Management Protocols (PACMPs), and Product Lifecycle Management (PLCM) concepts. In particular, the guideline emphasizes the relationship between Regulatory Assessment and GMP Inspection.
Furthermore, the guideline describes how ECs are identified as well as what information can be designated as supportive Information that would not require a regulatory submission, if changed. Guidance is also included for managing revisions of the ECs over a product’s lifecycle.
Presentations, case studies and open discussions will help participants learn more about the lifecycle management of pharmaceutical products / analytical methods and provide a forum for discussing ICH´s new guideline.
Participants will thus have the opportunity to give Feedback and ask questions directly to ICH´s Q12 Implementation Working Group (IWG) members on how to move forward with the transition to and implementation of the lifecycle approach.
The meeting will also address topics such as:
  • What are “Established Conditions” for Manufacture andControl?
  • How could Postapproval Change Management Protocols look like?
  • What is the impact of ICH Q12 on analytical method and process validation and transfer?
  • What are the views and expectations of assessors and inspectors?

Target Group

The ECA wishes to actively involve QA personnel dealing with global change management, analytical chemists, QC analysts, R&D scientists, as well as manufacturing scientists (process developers) and managers, and regulatory affairs specialists and regulators.

Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.
At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Programme

Provisional timetable, the actual schedule may vary depending on the situation.

Welcome and Introduction 09.00 - 09.15 h

09.15 - 10.00 h
PACMP - Postapproval Change Management Protocol
  • What is a PACMP?
  • Structure
  • Examples
10.00 - 10.45 h
Views and Expectations of Assessors (EU)
  • Current Status
  • Implementation in Europe
  • Application of Q12 tools on post approval changes: Case Studies
  • Lessons learned
Break 10.45 - 11.00 h

11.00 - 12.00 h
Change Implementation Control now and with ICH Q12
  • How we control change implementation today
  • How will ICH Q12 influence our future?
  • Simplification or new complexity?
  • QP considerations
12.00 – 12.30 h
Q&A Session 1

Break 12.30 - 13.30 h

13.30 - 14.30 h
Analytical Lifecycle Management
  • Overview on EFPIA/PhRMA Paper and the draft USP Chapter <1220>Alignment with manufacturing process
  • Analytical Target Profile (ATP)
  • Continuous improvement and regulatory flexibility
  • ICH Q12, Q2(revision), Q14
14.30 - 15.15 h
Post-approval CMC Changes -How to Use ICH Q12 effectively
  • Global Regulatory Complexity
  • Agile post-approval change management within ICH Q12 including examples for
    • Classification of changes
    • Established Conditions / PACMPs / PLCM
Break 15.15 - 15.30 h

15.30 - 16.30 h
Drug Product Lifecycle and ICH Q12 - FDA Perspective
  • Current Status
  • Implementation in US
  • Application of Q12 tools on post approval changes:
    • PACMP
    • EC
  • Lessons learned
16.30 – 17.00 h
Q&A Session 2

Go back

GMP Conferences by Topics